{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-018272","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.267809+00:00","generated_at":"2026-06-26T00:14:36.576179+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ARCA biopharma retains Ladenburg Thalmann for strategic options review","bullets":["Retained Ladenburg Thalmann & Co. Inc. as financial advisor for strategic review.","Board formed Special Committee in April 2022 to explore value-maximizing alternatives.","Potential alternatives include acquisition, merger, business combination, or other transaction.","No timetable set for review; no assurance that any transaction will result."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-018272","json":"https://secwatch.observer/filing/0001564590-22-018272.json","markdown":"https://secwatch.observer/filing/0001564590-22-018272.md","text":"https://secwatch.observer/filing/0001564590-22-018272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000156459022018272/0001564590-22-018272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000156459022018272/abio-8k_20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:14:36.576179+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}